Environmental

IQV’s environmental profile is broadly in line with peers because CRO operations are service-based and less emissions-intensive than laboratory or manufacturing-heavy healthcare peers.

The provided metrics show no R&D intensity, which limits direct environmental disclosure leverage versus peers that report more resource-intensive innovation footprints.

Absence of capital-intensive physical production reduces exposure to energy, water, and waste risks, but this is a sector trait rather than a clear peer advantage.

Environmental materiality remains moderate because the business model’s main ESG exposure is indirect through supplier and facility management practices rather than core process emissions.

Social

IQV’s social positioning is stronger than many peers because clinical research services depend on human-subject protection, informed consent, and protocol compliance as core operating requirements.

The company’s service model creates sustained exposure to patient safety, data privacy, and trial integrity expectations, which are material but generally manageable versus peers.

Low stock-based compensation relative to revenue suggests less pressure on employee alignment and retention costs than peers with heavier equity-based pay structures.

Social risk remains elevated by the industry’s reliance on global trial execution and third-party sites, but that exposure is common across peers rather than uniquely disadvantageous.

Governance

IQV’s leverage profile is a relative governance constraint because debt-to-equity and net debt-to-EBITDA are elevated, increasing oversight demands versus less levered peers.

Stock-based compensation at 1.6% of revenue is modest, which supports capital discipline relative to peers that rely more heavily on equity incentives.

The absence of R&D spending in the provided metrics limits visibility into governance around innovation allocation, but this is less material for a services model than for biopharma peers.

Overall governance is acceptable but not leading because balance-sheet leverage creates more monitoring complexity than the strongest peer group.

Overall Score

IQV is positioned as a solid but not leading ESG performer versus peers, with stronger social characteristics offset by moderate governance leverage and neutral environmental exposure.

Score Driver: Social Strengths From The Clinical Research Service Model Are The Main Relative Advantage.